New immune-boosting combo targets stubborn lymphoma
NCT ID NCT07125872
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of drugs (CD19 t-haNK, N-803, and rituximab) in 20 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors and improve survival. Participants will receive the treatment and be monitored for side effects and response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Albert Cellular Therapy
RECRUITINGPretoria, 0044, South Africa
-
Dr. Jackie Thomson Inc
RECRUITINGJohannesburg, 2193, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.